miR-29c has been investigated in a number of cancer settings with a number of confirmed targets identified, including integrin beta 1 (ITGB1) and matrix metalloproteinase 2 (MMP2) for which luciferase reporter assays confirming direct targeting of miR-29c has been previously reported18,19,25. Here, ITGB1 is linked to cancer.